Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
Objective: Sugemalimab is approved in China as a first-line treatment in combination with chemotherapy for metastatic nonsquamous non-small cell lung cancer (NSCLC). This study aims to evaluate the cost-effectiveness of first-line additional sugemalimab in combination with chemotherapy vs. chemother...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Kitap |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.,
2022-09-01T00:00:00Z.
|
| Konular: | |
| Online Erişim: | Connect to this object online. |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
Internet
Connect to this object online.3rd Floor Main Library
| Yer Numarası: |
A1234.567 |
|---|---|
| Kopya Bilgisi 1 | Kütüphanede |